Accession Number

Seven membered heterocyclic rings containing a NITROGEN atom.

DrugDrug Description
QuetiapineA psychotropic agent used for the management of bipolar disorder, schizophrenia, and major depressive disorder.
MeptazinolNot Annotated
DilazepNot Annotated
PentetrazolA cough suppressant.
OmapatrilatFor the treatment of hypertension.
Paratoulene phosphateNot Available
TAK-475Investigated for use/treatment in hyperlipidemia.
TemocaprilTemocapril is an ACE inhibitor primarily indicated in the treatment of hypertension and congestive heart failure, diabetic nephropathy, and improvement of prognosis for coronary artery diseases (including acute myocardial infarction).
TianeptineAn atypical tricyclic antidepressant with antidepressant and anxiolytic effects primarily used to treat major depressive disorder.
GSK-2330672GSK2330672 has been investigated for the treatment of Diabetes Mellitus, Type 2.
TaselisibTaselisib has been used in trials studying the treatment and basic science of LYMPHOMA, Breast Cancer, Ovarian Cancer, Solid Neoplasm, and HER2/Neu Negative, among others.
PiclozotanPiclozotan has been investigated for the treatment of Parkinson's Disease.
EleclazineEleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.
ElobixibatElobixibat has been used in trials studying the treatment and basic science of Dyslipidemia, Constipation, Chronic Constipation, Functional Constipation, and Chronic Idiopathic Constipation.
PF-04620110PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).
ZiresovirZiresovir is under investigation in clinical trial NCT03699202 (Anti-RSV Study in Chinese Patients (ASCENT)).
BrensocatibBrensocatib is under investigation in clinical trial NCT03218917 (Assessment of INS1007 in Subjects With Non-cystic Fibrosis Bronchiectasis).
LapaquistatLapaquistat is under investigation in clinical trial NCT00256178 (Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.).
Drugs & Drug Targets
Quetiapine5-hydroxytryptamine receptor 2Atarget
Quetiapine5-hydroxytryptamine receptor 2Ctarget
QuetiapineDopamine D2 receptortarget
Quetiapine5-hydroxytryptamine receptor 1Atarget
QuetiapineHistamine H1 receptortarget
QuetiapineCytochrome P450 3A4enzyme
QuetiapineAlpha-1 adrenergic receptorstarget
QuetiapineAlpha-2A adrenergic receptortarget
QuetiapineAlpha-2B adrenergic receptortarget
QuetiapineAlpha-2C adrenergic receptortarget
Quetiapine5-hydroxytryptamine receptor 1Dtarget
QuetiapineMuscarinic acetylcholine receptor M1target
QuetiapineMuscarinic acetylcholine receptor M2target
QuetiapineMuscarinic acetylcholine receptor M3target
QuetiapineMuscarinic acetylcholine receptor M4target
QuetiapineMuscarinic acetylcholine receptor M5target
Quetiapine5-hydroxytryptamine receptor 1Btarget
Quetiapine5-hydroxytryptamine receptor 1Etarget
Quetiapine5-hydroxytryptamine receptor 3Atarget
Quetiapine5-hydroxytryptamine receptor 6target
Quetiapine5-hydroxytryptamine receptor 7target
QuetiapineDopamine D5 receptortarget
QuetiapineDopamine D1 receptortarget
QuetiapineDopamine D3 receptortarget
QuetiapineDopamine D4 receptortarget
QuetiapineCytochrome P450 3A5enzyme
QuetiapineP-glycoprotein 1transporter
QuetiapineCytochrome P450 2C19enzyme
QuetiapineCytochrome P450 2D6enzyme
QuetiapineCytochrome P450 3A7enzyme
OmapatrilatAngiotensin-converting enzymetarget
Paratoulene phosphateProto-oncogene tyrosine-protein kinase Srctarget
TAK-475Squalene synthasetarget
TAK-4753-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
TemocaprilSolute carrier family 15 member 1transporter
TemocaprilSolute carrier organic anion transporter family member 1A2transporter
TemocaprilAngiotensin-converting enzymetarget
TianeptineGlutamate receptor 1target
TianeptineMu-type opioid receptortarget
Tianeptine5-hydroxytryptamine receptor 1Atarget
TianeptineDopamine D3 receptortarget
TianeptineCytochrome P450 3A4enzyme